Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies, Inc. (PTN) generates a steady flow of news as a biopharmaceutical company centered on melanocortin receptor–based therapeutics. News coverage for PTN often highlights updates on its obesity, ocular, and retinal programs, as well as financing events and stock listing developments. Investors and followers can use this page to review how Palatin’s scientific, clinical, and corporate milestones evolve over time.
Recent press releases have focused on obesity program progress, including preclinical and clinical data for the oral MC4R agonist PL7737 and next-generation peptide MC4R agonists. Palatin has reported robust weight loss and favorable safety in preclinical models, Phase 2 data on co-administration of an MC4R agonist with tirzepatide in obese patients, and regulatory designations such as Orphan Drug status for PL7737 in LEPR deficiency–related obesity. These updates provide insight into the company’s efforts to develop mechanism-based obesity therapies.
Palatin news also covers its ocular and retinal pipeline. Releases describe Phase 3 MELODY-1 data for PL9643 in dry eye disease, including responder analyses showing complete symptom resolution across multiple endpoints, and preclinical findings for PL9654 and PL9655 in diabetic retinopathy that demonstrate inflammation resolution, vascular stabilization, and neuroprotection. Announcements related to the company’s collaboration with Boehringer Ingelheim for retinal diseases further illustrate how Palatin seeks to advance its melanocortin platform through partnerships.
On the corporate side, PTN news items detail public offerings, warrant structures, and exchange listing status, including NYSE American delisting proceedings, trading on OTC markets, a 1-for-50 reverse stock split, and the subsequent resumption of trading on NYSE American. For readers tracking PTN, this news feed brings together scientific presentations, clinical trial readouts, collaboration agreements, and capital markets activity in one place, making it easier to follow Palatin’s development trajectory and key disclosures.
Palatin Technologies (NYSE American: PTN) announced the completion of patient enrollment for its Phase 2 study of PL9643 aimed at treating dry eye disease (DED). The study, which resumed enrollment after COVID-19 delays, aims to evaluate PL9643's efficacy and safety compared to a placebo. With data readout expected in Q4 2020, Palatin emphasizes the potential of PL9643 to offer a quick onset of efficacy and a favorable safety profile, addressing the needs of patients who struggle with existing therapies for DED.
Palatin Technologies (PTN) announced the mutual termination of its January 2017 license agreement with AMAG Pharmaceuticals, regaining North American rights to Vyleesi® (bremelanotide), the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. AMAG will pay Palatin $12 million at closing and $4.3 million on March 31, 2021. Palatin will take over Vyleesi's manufacturing and commercialization, ensuring uninterrupted patient access. The company aims to explore strategic partnerships to enhance Vyleesi's marketing, stressing its commitment to affordable access for women affected by HSDD.
Palatin Technologies (NYSE American: PTN) announced the development of PL8177 as a potential treatment for COVID-19 patients experiencing hypoxemic respiratory failure. The decision is based on positive preclinical results showing PL8177's efficacy in reducing inflammation and lung damage. The company plans to submit an IND application in Q3 2020 and initiate a Phase 2 trial in Q4 2020, following successful preclinical and Phase 1 studies. The trial will evaluate the effectiveness of PL8177 against a placebo in hospitalized adult patients with severe COVID-19 symptoms.